a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
about
Systemic therapy for cervical cancer with potentially regulatable oncolytic adenovirusesSystemic delivery of oncolytic viruses: hopes and hurdlesImmune recruitment and therapeutic synergy: keys to optimizing oncolytic viral therapy?The history of tumor virologyIntelligent design: combination therapy with oncolytic virusesCurrent developments in adenovirus-based cancer gene therapyIn Vivo Noninvasive Imaging for Gene TherapyTaking Gene Therapy into the ClinicMathematical modeling of tumor therapy with oncolytic viruses: regimes with complete tumor elimination within the framework of deterministic models.Microneedles As a Delivery System for Gene TherapyshRNA-armed conditionally replicative adenoviruses: a promising approach for cancer therapyTargeting adeno-associated virus and adenoviral gene therapy for hepatocellular carcinomaEvidence for Oncolytic Virotherapy: Where Have We Got to and Where Are We Going?Chemovirotherapy: combining chemotherapeutic treatment with oncolytic virotherapyAdenovirus vectors for gene therapy, vaccination and cancer gene therapyLessons learned from next-generation sequencing in head and neck cancerRole of microRNAs in hepatocellular carcinoma: a clinical perspectiveClinical trials with oncolytic reovirus: moving beyond phase I into combinations with standard therapeutics.Virotherapy: cancer gene therapy at last?Chemoresistance and targeted therapies in ovarian and endometrial cancersOncolytic adenovirus research evolution: from cell-cycle checkpoints to immune checkpointsCancer gene therapy using a survivin mutant adenovirusIntrathecal gene therapy for treatment of leptomeningeal carcinomatosis.Enhanced tumor uptake and penetration of virotherapy using polymer stealthing and focused ultrasoundThe relationship between terminal functionalization and molecular weight of a gene delivery polymer and transfection efficacy in mammary epithelial 2-D cultures and 3-D organotypic culturesThe future of laryngology.Efficient generation of double heterologous promoter controlled oncolytic adenovirus vectors by a single homologous recombination step in Escherichia coliMathematical modeling of tumor therapy with oncolytic viruses: effects of parametric heterogeneity on cell dynamics.Prevention of chemotherapy-related toxic side effects by infection with adeno-associated virus type 2.Directed evolution generates a novel oncolytic virus for the treatment of colon cancerAlternate serotype adenovector provides long-term therapeutic gene expression in the eye.Cycles of transient high-dose cyclophosphamide administration and intratumoral oncolytic adenovirus vector injection for long-term tumor suppression in Syrian hamstersRecombinant measles viruses efficiently entering cells through targeted receptorsTargeting p53 for Novel Anticancer Therapy.Virotherapy against malignant glioma stem cellsAltered expression of antiviral cytokine mRNAs associated with cyclophosphamide's enhancement of viral oncolysisAdvances in preclinical investigation of prostate cancer gene therapy.Calcium gluconate in phosphate buffered saline increases gene delivery with adenovirus type 5.Current issues and future directions of oncolytic adenoviruses.Squamous cell carcinomas of the head and neck.
P2860
Q21144267-328986A2-9F0F-41CC-9322-F99C842C02B0Q21284969-5D0456DF-4EDB-4FD8-B21D-1915C8B92885Q24596171-71A4520B-5E25-4EB1-8AA3-A13A5094155CQ24610004-6BD01D76-D730-4423-89DC-A56430C76978Q24628227-ED9BC9BE-A69C-4AC5-AEE3-CBCBCCC9D0E4Q24683229-5A64E842-C922-4A45-A387-A34088B61B93Q24790997-42286072-BA0F-4332-A76D-FC8AC0E22220Q24792911-EF1782F8-F50D-426F-B6C9-CF8888ACA443Q25257260-17605A1C-A16A-4880-85D1-88A5BA57559AQ26746026-24229F48-58C9-4D6B-B19D-5E4B19DB7ADCQ26765364-F1060C82-D278-45EF-86C1-C21049076A92Q26772315-149A600A-9CDB-4FD8-908F-E114F1CD8202Q26775030-C02D727F-DC8F-405F-A939-D94ACC2E3AEEQ26852345-248C1DDE-21C5-4E4A-A2A0-AC2E2F220396Q27001601-2D6862BC-3CD5-48E2-9387-8E29A32400DBQ27009209-5F6C556F-16A1-4A3E-BEFC-2EA02944C8CFQ27014034-912A2273-968E-4219-8464-C1DADA8DDB44Q27690634-2F0A7B23-2D33-443D-BB7F-07316F688555Q28066228-5612D0CC-C969-4799-BAFD-45EE9AD88655Q28073246-2BE4121C-52AD-4698-8D68-93541BE20C8EQ28083515-99F07AD2-CD2C-4E9A-8D9D-049234EC42F3Q28360690-674F826E-FECD-4182-AA1C-2FB856DAEA8AQ30425756-009561EB-8CC7-48BF-AE75-EE4910445CD8Q30446996-53EC7546-A900-4848-BBBC-865BB4726672Q30504481-2B0A75A5-6164-4178-8732-D8A8CF164140Q30767260-F53888B6-8B72-43B1-87BC-15D165529ED1Q33252754-60E336B6-49CC-42BA-93F3-625C01E0E73EQ33259239-5694DF4F-FC6C-4A0D-BA56-6BE84F6ECE08Q33343268-223A252F-9EFC-465C-8D2D-87808D9B3360Q33344440-493FCB2A-4E26-447B-90E5-7EE66CEBEBB2Q33397385-73D366C3-810C-4B7C-B5C3-195928C342D7Q33580223-F6DA74FD-1792-4400-9892-3E9D02A08F40Q33603475-0B845C85-7D97-4A1F-A5D6-7960B5F0526DQ33655329-8079A061-5D84-4BA4-B090-6E0D83F40B73Q33665530-302703C0-5A60-4C16-9920-7DE2A0869B1DQ33675567-C9CCC1AC-DECE-4956-9D71-B0D28EC5DD2CQ33677054-8FBCD8CC-832A-47FE-88A7-F643121AD13FQ33711997-625B8094-1F61-4E91-B0A2-50569E19B896Q33730705-AC2FCA0E-885D-4740-BDC3-11E4BB643767Q33812371-31FD7EF6-FC58-4AAC-830A-17B8A23384F4
P2860
a controlled trial of intratumoral ONYX-015, a selectively-replicating adenovirus, in combination with cisplatin and 5-fluorouracil in patients with recurrent head and neck cancer.
description
2000 nî lūn-bûn
@nan
2000 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2000 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2000年の論文
@ja
2000年論文
@yue
2000年論文
@zh-hant
2000年論文
@zh-hk
2000年論文
@zh-mo
2000年論文
@zh-tw
2000年论文
@wuu
name
a controlled trial of intratum ...... ecurrent head and neck cancer.
@ast
a controlled trial of intratum ...... ecurrent head and neck cancer.
@en
type
label
a controlled trial of intratum ...... ecurrent head and neck cancer.
@ast
a controlled trial of intratum ...... ecurrent head and neck cancer.
@en
prefLabel
a controlled trial of intratum ...... ecurrent head and neck cancer.
@ast
a controlled trial of intratum ...... ecurrent head and neck cancer.
@en
P2093
P356
P1433
P1476
a controlled trial of intratum ...... ecurrent head and neck cancer.
@en
P2093
Arseneau J
Gillenwater AM
Ironside J
P2888
P304
P356
10.1038/78638
P407
P577
2000-08-01T00:00:00Z
P6179
1009134605